Endothelial stem cell therapy - CellProThera

Drug Profile

Endothelial stem cell therapy - CellProThera

Latest Information Update: 08 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CellProthera
  • Class Cardiovascular therapies; Stem cell therapies
  • Mechanism of Action Endothelial cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Myocardial infarction

Most Recent Events

  • 30 Oct 2018 CellProThera and BioCardia extends agreement of the phase I/IIb EXCELLENT trial of Protheracytes® in Myocardial infarction in Singapore
  • 01 Oct 2015 Phase-I/II clinical trials in Myocardial infarction in United Kingdom (Intracardiac) (NCT02669810, EudraCT 2014-001476-63) after October 2015
  • 15 Sep 2014 Preclinical trials in Myocardial infarction in France (Intramyocardial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top